Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Arthritis, Rheumatoid 6 Colitis, Ulcerative 3 Spondylitis, Ankylosing 1 Recurrence 1 Prostatic Neoplasms 1 Lymphoma 1 Inflammatory Bowel Diseases 1 Infections 1 Diabetes Mellitus, Type 1 1 Crohn Disease 1

Interventions

otelixizumab 1 golimumab 1 Waist-Hip Ratio 1 Waist Circumference 1 Time 1 Sex Characteristics 1 Islets of Langerhans Transplantation 1 Insulin 1 High-Intensity Interval Training 1 Exenatide 1 Etanercept 1 Echocardiography 1 Continuous Glucose Monitoring 1 Cardiovascular Physiological Phenomena 1 Body Mass Index 1 Body Composition 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Diabetes Mellitus, Type 1 × golimumab × Clear all

NCT04729296 2021-12-02

Anti-TNFα to Delay or Prevent Progression to Stage 3 T1D

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Phase 2 Withdrawn

Diabetes Mellitus, Type 1

Data powered by HemOnc (CC BY 4.0) Colophon ⚡